A clinical study of RLF-100TM (aviptadil) in severe COVID-19 induced lung injury
Latest Information Update: 01 Dec 2020
At a glance
- Drugs Aviptadil (Primary)
- Indications Lung injury
- Focus Adverse reactions
- 01 Dec 2020 New trial record
- 18 Nov 2020 According to a RELIEF THERAPEUTICS Holding media release, the company has appointed Syneos Health to run this trial as well as future trials in other indications to be conducted in Europe.